Literature DB >> 10964988

Construction of a diabody (small recombinant bispecific antibody) using a refolding system.

S Takemura1, R Asano, K Tsumoto, S Ebara, N Sakurai, Y Katayose, H Kodama, H Yoshida, M Suzuki, K Imai, S Matsuno, T Kudo, I Kumagai.   

Abstract

Diabodies are the recombinant bispecific antibodies (BsAbs), constructed from heterogeneous single-chain antibodies. Usually, diabodies have been prepared from bacterial periplasmic fraction using a co-expression vector (i.e. genes encoding two chains were tandemly located under the same promoter). Some diabodies, however, cannot be expressed as a soluble material owing to inclusion body formation, which limits the utilization of diabodies in various fields. Here we report an improved method for the construction of diabodies using a refolding system. As a model, a bispecific diabody binding to adenocarcinoma-associated antigen MUC1 and to CD3 on T cells was studied. One chain consisted of a VH specific for MUC1 linked to a VL specific for CD3 with a short polypeptide linker (GGGGS). The second was composed of a VL specific for MUC1 linked to a VH specific for CD3. The two hetero scFvs were independently obtained from intracellular insoluble fractions of Escherichia coli, purified, mixed stoichiometrically (at an equivalent molar ratio of 1:1) and refolded. The refolded two hetero scFv has a hetero-dimeric structure, with complete specificity for both target cells [i.e. MUC1 positive cells and CD3 positive lymphokine-activated killer cells with a T cell phenotype (T-LAK)]. Evaluation of the in vitro efficacy of T-LAK with the diabody by growth inhibition assay of cancer cells demonstrated maximum growth inhibition of cancer cells to reach approximately 98% at an effector:target ratio (E:T ratio) of 10, almost identical with that with anti-MUC1xanti-CD3 chemically synthesized BsAbs (c-BsAbs). This is the first report of the construction of a diabody using a refolding system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964988     DOI: 10.1093/protein/13.8.583

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  7 in total

1.  Construction of non-covalent single-chain Fv dimers for hepatocellular carcinoma and their biological functions.

Authors:  Cai-Qun Bie; Dong-Hua Yang; Xu-Jing Liang; Shao-Hui Tang
Journal:  World J Hepatol       Date:  2010-05-27

2.  Recombinant Actinobacillus actinomycetemcomitans cytolethal distending toxin proteins are required to interact to inhibit human cell cycle progression and to stimulate human leukocyte cytokine synthesis.

Authors:  S Akifusa; S Poole; J Lewthwaite; B Henderson; S P Nair
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 3.  scFv antibody: principles and clinical application.

Authors:  Zuhaida Asra Ahmad; Swee Keong Yeap; Abdul Manaf Ali; Wan Yong Ho; Noorjahan Banu Mohamed Alitheen; Muhajir Hamid
Journal:  Clin Dev Immunol       Date:  2012-03-15

4.  A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.

Authors:  Aruto Sugiyama; Mitsuo Umetsu; Hikaru Nakazawa; Teppei Niide; Tomoko Onodera; Katsuhiro Hosokawa; Shuhei Hattori; Ryutaro Asano; Izumi Kumagai
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

5.  Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance.

Authors:  Saori Suzuki; Hiroaki Annaka; Shota Konno; Izumi Kumagai; Ryutaro Asano
Journal:  Sci Rep       Date:  2018-11-22       Impact factor: 4.379

Review 6.  Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers.

Authors:  Mukulika Bose; Pinku Mukherjee
Journal:  Vaccines (Basel)       Date:  2020-11-05

7.  Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach.

Authors:  Asami Ueda; Mitsuo Umetsu; Takeshi Nakanishi; Kentaro Hashikami; Hikaru Nakazawa; Shuhei Hattori; Ryutaro Asano; Izumi Kumagai
Journal:  Int J Mol Sci       Date:  2020-01-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.